The estimated Net Worth of Joseph Douglas Lyon is at least $508 Mille dollars as of 1 July 2024. Mr Lyon owns over 5,000 units of Corcept Therapeutics Inc stock worth over $508,010 and over the last 4 years he sold CORT stock worth over $0.
Mr has made over 19 trades of the Corcept Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of CORT stock worth $56,750 on 1 July 2024.
The largest trade he's ever made was exercising 50,000 units of Corcept Therapeutics Inc stock on 30 December 2020 worth over $395,000. On average, Mr trades about 6,964 units every 46 days since 2020. As of 1 July 2024 he still owns at least 14,290 units of Corcept Therapeutics Inc stock.
You can see the complete history of Mr Lyon stock trades at the bottom of the page.
Joseph Douglas Lyon is the Chief Accounting Officer at Corcept Therapeutics Inc.
Mr Lyon is 42, he's been the Chief Accounting Officer of Corcept Therapeutics Inc since . There are 17 older and no younger executives at Corcept Therapeutics Inc. The oldest executive at Corcept Therapeutics Inc is George Baker, 77, who is the Independent Director.
Joseph's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson e Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: